ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry")

被引：0

作者：

Cecchi, Irene ^{[1
,2
,3
]}

Radin, Massimo ^{[1
,2
,3
]}

Foddai, Silvia Grazietta ^{[1
,2
,3
]}

Barinotti, Alice ^{[1
,2
,3
]}

Andrade, Danieli ^{[4
]}

Tektonidou, Maria G. ^{[5
]}

Pengo, Vittorio ^{[6
]}

Ruiz-Irastorza, Guillermo ^{[7
]}

Belmont, H. Michael ^{[8
]}

Pedrera, Chary Lopez ^{[9
]}

Fortin, Paul R. ^{[10
]}

Gerosa, Maria ^{[11
]}

de Jesus, Guilherme ^{[12
]}

Atsumi, Tatsuya ^{[13
]}

Ji, Lanlan ^{[14
]}

Efthymiou, Maria ^{[15
]}

Branch, D. Ware ^{[16
,17
]}

Nalli, Cecilia ^{[18
]}

Rodriguez-Almaraz, Esther ^{[19
]}

Petri, Michelle ^{[20
]}

Cervera, Ricard ^{[21
]}

Knight, Jason S. ^{[22
]}

Artim-Esen, Bahar ^{[23
]}

Willis, Rohan ^{[24
]}

Bertolaccini, Maria Laura ^{[25
]}

Cohen, Hannah ^{[15
]}

Erkan, Doruk ^{[26
]}

Sciascia, Savino ^{[1
,2
,3
]}

机构：

[1] San Giovanni Bosco Hub Hosp, Univ Ctr Excellence Nephrol Rheumatol & Rare Dis, ERK Net ERN Reconnect & RITA ERN, Nephrol & Dialysis Unit, I-10154 Turin, Italy

[2] San Giovanni Bosco Hub Hosp, Ctr Immunorheumatol & Rare Dis CMID, Coordinating Ctr Interreg Network Rare Dis Piedmon, I-10154 Turin, Italy

[3] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

[4] Univ Sao Paulo, Sao Paulo, Brazil

[5] Natl & Kapodistrian Univ Athens, Athens, Greece

[6] Univ Padua, Padua, Italy

[7] Univ Basque Country, Biobizkaia Hlth Res Inst, Autoinmune Dis Res Unit, Baracaldo, Spain

[8] NYU, Langone Med Ctr, New York, NY USA

[9] Univ Cordoba, Reina Sofia Univ Hosp, Dept Med & Surg Sci, Rheumatol Serv,Maimonides Inst Res Biomed Cordoba, Cordoba, Spain

[10] Univ Laval, Ctr ARThr, CHU Quebec, Quebec City, PQ, Canada

[11] Univ Milan, Milan, Italy

[12] Univ Estado Rio de Janeiro, Rio De Janeiro, Brazil

[13] Hokkaido Univ Hosp, Sapporo, Japan

[14] Peking Univ First Hosp, Beijing, Peoples R China

[15] UCL, London, England

[16] Univ Utah, Salt Lake City, UT USA

[17] Intermt Healthcare, Salt Lake City, UT USA

[18] Univ Brescia, Brescia, Italy

[19] Hosp Univ 12 Octubre, Madrid, Spain

[20] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[21] Univ Barcelona, Hosp Clin, Dept Autoimmune Dis, IDIBAPS, Barcelona, Catalonia, Spain

[22] Univ Michigan, Ann Arbor, MI USA

[23] Istanbul Univ, Sch Med, Istanbul, Turkiye

[24] Univ Texas Med Branch, Galveston, TX USA

[25] Kings Coll London, Sch Cardiovasc & Metab Med & Sci, London, England

[26] Hosp Special Surg, Barbara Volcker Ctr Women & Rheumat Dis, Weill Cornell Med, New York, NY USA

来源：

RHEUMATOLOGY | 2024年

关键词：

antinuclear antibodies; antiphospholipid antibodies; antiphospholipid syndrome; phenotyping; MANIFESTATIONS; CRITERIA; UPDATE; COHORT;

D O I：

10.1093/rheumatology/keae583

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: This study focused on the prevalence and impact of ANA in aPL-positive patients without concomitant systemic autoimmune rheumatic diseases (SARDs). Methods: Data from aPL-positive patients with or without Revised Sapporo APS classification criteria were retrieved from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry. Patients with concomitant SARDs were excluded. Results: A total of 430 aPL-positive patients were included in the analysis, 56% ANA-positive (ANA+) and 44% ANA-negative (ANA-). ANA positivity was significantly associated with history of haematologic manifestations (persistent autoimmune haemolytic anaemia, thrombocytopenia, leukopenia and/or lymphopenia) (16% of ANA+ vs 7% of ANA-, P = 0.006). Triple aPL-positivity was more frequent in the ANA+ subgroup (P = 0.02), along with low baseline C3 and C4 levels (P = 0.05 and P = 0.009, respectively), and higher frequency for ENA. Among aPLpositive patients with no APS classification, ANA+ patients showed a higher rate of arthritis (P = 0.006). Among female patients who have experienced at least one pregnancy, 113 were ANA+ and 96 were ANA-; ANA- patients had a higher number of pregnancies (P = 0.018), and number of live births (P = 0.014). A wider proportion of ANA+ patients were treated with HCQ (P < 0.001). Conclusion: When we analysed aPL-positive patients with no other SARDs, ANA status was not associated with thrombosis or pregnancy morbidity. Interestingly, ANA+ patients showed higher rates of systemic autoimmune features, including haematologic manifestations, multiple aPL positivity, lower complement levels, ENA positivity, and joint involvement, and were more often treated with HCQ. Finally, aPL-positive subjects who were ANA- had a higher rate of pregnancies and live births.

引用

页数：6

共 22 条

[21] CLINICAL ANALYSIS OF ANTICARDIOLIPIN BETA-2 GLYCOPROTEIN-1 ANTIBODY-POSITIVE PATIENTS IN ANTIPHOSPHOLIPID SYNDROME
KATAYAMA, I
NISHIOKA, K
OTOYAMA, K
JOURNAL OF DERMATOLOGICAL SCIENCE, 1995, 9 (03) : 215 - 220
[22] 2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria solid phase-based antiphospholipid antibody domain-collaborative efforts of Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking and ISTH SSC to harmonize enzyme-linked immunosorbent assay and non-enzyme-linked immunosorbent assay antiphospholipid antibody tests: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
Meroni, Pier Luigi
Borghi, Maria Orietta
Amengual, Olga
Atsumi, Tatsuyaa
Bertolaccini, Maria Laura
Cohen, Hannah
Grossi, Claudia
Roubey, Robert
Sciascia, Savino
Tebo, Anne
Willis, Rohan
Erkan, Doruk
Devreese, Katrien M. J.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2025, 23 (01) : 341 - 344

← 1 2 3 →